Drug Trial Radar · NCT00940784
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Last checked: Nov 19, 2026Latest source record: Nov 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 2009
Primary completion
Jan 2011
Study completion Jan 2011
Sponsor
- Lead sponsor
- Ronald HoffmanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI)
- First posted
- Jul 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 81 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clopidogrel (Plavix) and aspirin are two antithrombotic agents (blood thinners) commonly used in patients with previous thrombotic events (stroke or heart attack). Thrombosis is the formation of a blood clot in a blood vessel. Patients with polycythemia vera are routinely treated with aspirin which has been shown to be effective in reducing their thrombotic risk. However, in polycythemia vera patients with previous thrombosis, a further benefit might be obtained by using the combination of aspirin and clopidogrel which is routinely used in patients with recent acute myocardial ischemia (reduced blood supply to the heart muscle). The study will assess whether this combination therapy greatly increases the risk of bleeding versus aspirin alone, if clopidogrel reduces biological factors that might lead to a stroke or heart attack, and whether a high number of patients with polycythemia vera are resistant to clopidogrel. Approximately 200 subjects will be enrolled to the Myeloproliferative Disorders-Research Consortium (MPD-RC) study in Europe and the United States with participation expected to last for 7 months (6 months of receiving study medication plus a 30 day follow-up visit).
Conditions
- Polycythemia Vera
Interventions
Clopidogrel (Plavix)Drug
Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
PlaceboDrug
Placebo, aspirin (81-100 mg qd) plus hydroxyurea
AspirinDrug
81-100 mg qd
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety and efficacy of using Clopidogrel plus aspirin on Polycythemia Vera patientsTime frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.